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Abstract 
The immune system is normally tolerant o mitochondrial self-antigens, but responsive against bacteria. Low-titre anti-mitochondrial 
antibodies (AMA) might be involved in this discrimination. Tolerance is broken in diseases characterised by high titre AMA. Some of 
these AMA, against cardiolipin, cross-react with DNA. The best studied AMA are those characterising primary biliary cirrhosis (PBC). 
These are directed against E2 subunits of the oxo-acid dehydrogenase complexes, and also against subunits E1 a, El/3 and X of the 
pyruvate dehydrogenase complex. AMA of PBC patients also react with bacterial E2s. Reactivities are primarily peptide-specific but with 
cross-reactivity between mitochondrial nd microbial antigens and between E2s of respective complexes. Immunodominant epitopes, for 
anti E2 AMA, include the conserved sequence flanking the site of lipoyl attachment. It is proposed that the initial stimulus for antibody 
production is chronic urinary tract infection. AMA themselves are not pathogenic, but CD4 + T-cells would be primed, recognising the 
lipoyl domain epitope in association with class II HLA. Inappropriate xpression of class II antigens on bile duct epithelia, (as found in 
PBC), might lead to presentation of a particular fragment of HLA-DR a, known to be a major MHC presented self-peptide in the mouse. 
That sequence strongly mimics the lipoyl domain and might be recognised by primed T-cells, initiating the autoimmune cascade. In the 
mouse, a peptide of NDI of Complex I is presented in association with class I MHC. Cells exhibiting somatic mutation of such a peptide 
might thus be subject to attack by CD8 + T-cells. If such peptides were presented by class II HLA, autoimmune diseases might arise, 
related to mimicry between such peptides and microbial sequences and/or self-antigens. These considerations might apply in Leber's 
disease and in age-related pathology. 
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1. Introduction 
The origin of mitochondria s endosymbionts, with a 
residual genome subject to a high mutation rate, raises 
numerous questions of complex genetics and elaborate 
control of assembly and function. It is those very features 
which underlie the many diseases discussed elsewhere in 
this volume. Those features also raise interesting questions 
in immunology. 
On the one hand, the abundance of mitochondria in 
most cells would seem to assure that, during development, 
T-cell clones, with receptors recognising all characteristic 
mitochondrial peptides in association with self-MHC 
molecules, would have been eliminated or anergised. On 
the other hand, it is noteworthy that, in the mouse, a minor 
class I-like MHC antigen is co-expressed with a peptide 
derived from the mitochondrially coded ND1 subunit of 
Complex I [1,2], as the so called maternally transmitted 
transplantation antigen, Mtf. In other words, not only 
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should the immune system be tolerant to self-peptides of 
mitochondrial origin, it also may be primed to reject 
tissues expressing mutated mitochondrial peptides. 
That latter issue will not be considered in detail here. 
except for one specific case (see later). However, the 
subtle clinical manifestations of mitochondrial diseases 
may well include the effects of immunosurveillance against 
mutant peptides; and that is still a virgin topic for future 
research. Conversely, tolerance to self-peptides needs to be 
balanced against immuno-competence against those very 
bacteria to which mitochondria re phylogenetically re- 
lated. 
2. Naturally occurring mitochondrial antibodies 
Evidence that some such subtle control mechanism 
exists within the feed-back network of the immune system 
is the well-established existence of low titres of naturally 
occurring mitochondrial antibodies (NOMA) in normal 
populations [3,4]. If a sensitive Western blotting assay is 
used against, say, bovine heart mitochondria, a very large 
number of antibody specificities (both IgG and IgM) are 
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usually detected, with large individual variations, partly 
correlated with clinical histories of infection. The corre- 
sponding antigens for these NOMA have not been identi- 
fied; it is conceivable that they constitute 'biographical 
fingerprints', that might even be of forensic value. 
3. Anti-mitochondrial autoantibodies 
However there are some circumstances when self toler- 
ance breaks down, as manifest by very high titres of 
specific anti-mitochondrial autoantibodies (AMA) associ- 
ated with certain diseases. The full range of such condi- 
tions is reviewed elsewhere [5]. In most cases there is little 
clear evidence of the role (if any) of the AMA in the 
pathogenesis of the disease (be it infectious, drug induced 
or idiopathic), the precise identity of the autoantigen(s) or
(even if the antigens have been identified) the basis for the 
specific production of those particular AMA. 
The most interesting eneral point that arises from that 
cluster of conditions is that AMA are frequently detected 
against a number of epitopic configurations of cardiolipin, 
some of which are also detected as antinuclear antibodies 
[6]. This is presumably because of the similarity of the 
ribose phosphate backbone of nucleic acids to the glycerol 
phosphate arrays in cardiolipin micelles. Since any mito- 
chondrial disease might lead to increased turnover of 
mitochondria nd extracellular release of cardiolipin, that 
class of antibody might be of wide significance. 
4. Primary bUiary cirrhosis 
There is one disease where very high titres of AMA of 
a particular specificity are absolute stigmata, and where 
those antibodies not only give a clue as to pathogenesis of
the disease, but also suggest general principles that might 
underlie all autoimmune processes. That disease is primary 
biliary cirrhosis (PBC). 
PBC is a chronic, cholestatic liver disease, predomi- 
nantly affecting middle-aged women. It is characterised by
spontaneous inflammatory damage to epithelial cell of the 
bile duct, eventually leading to fibrosis [7]. The obstruction 
of intrahepatic biliary ductules leads initially to 'spillover' 
of biliary constituents, causing jaundice and severe itching, 
but the inexorable nd stage of the disease is cirrhotic liver 
failure. However, clinical presentation a d disease progres- 
sion are quite variable, so that for many years the disease 
may be virtually asymptomatic. 
Originally, PBC was considered to be extremely rare 
but better diagnosis of early cases has enabled a more 
accurate stimate to be made of its incidence. For example, 
in Northern Europe the prevalence is now considered to be 
between 90 and 150 cases per million [8], and in Europe 
PBC is now the commonest reason for liver transplanta- 
tion. 
The disease is much more common in women than in 
men, with an incidence ratio of around 10:1 [9]. There is 
no obvious geographical c ustering and there is no clear 
genetic linkage, although there is reported to be an associa- 
tion of PBC with the histocompatibility marker HLA-DR8 
[10]. Although the most clinically significant pathology 
focuses attention to the liver, PBC is, in fact, a multi-sys- 
tem disorder. It is usually characterised by salivary, 
lacrimal and pancreatic hyposecretion, so that strictly 
speaking it is a 'dry gland' syndrome [11]. It is also 
sometimes difficult to identify the specific immunological 
features of the disease itself against a background of its 
frequent association with a range of other autoimmune 
diseases, from rheumatoid arthritis to thyroiditis [12]. 
Nevertheless, there is no doubt that PBC is itself an 
autoimmune disease [13,14]. There are characteristic B- 
lymphocyte anomalies, particularly high levels of immuno- 
globulins, notably of the IgG3 subclass, and a spectrum of 
autoantibodies, both IgG and IgM. These include, in addi- 
tion to very high titres of AMA, antibodies to organ 
specific targets uch as thyroglobulin [15], and to a range 
of nuclear antigens [16-20], some of which seem to be 
disease specific; e.g., those against an integral membrane 
glycoprotein of molecular mass 210 kDa. There are also 
circulating immune complexes, thought o contain mito- 
chondrial antigens. 
In addition to B-cell defects, PBC is characterised by 
abnormalities of T-lymphocytes [7,21]. For example, there 
are functional deficiencies and decreased numbers of both 
CD4 + and CD8 + cells in periferal blood. Significantly, 
biliary ductules are infiltrated by T-cells, both CD8 + and 
CD4 +, and granulomatoma re often present [22]. 
Immunoglobulin deposits have also been detected on the 
surface of biliary epithelia [23]. 
Another very significant feature of the biliary epithelial 
cells in PBC is their inappropriate expression of class II 
molecules of the major histocompatibility complex (MHC) 
[24]. Such class lI molecules, (HLA-DR and -DQ), which 
are concerned with presentation of antigenic peptides to 
helper T-cells, are normally restricted to 'antigen-present- 
ing' cells, such as dendritic cells, macrophages and B- 
lymphocytes. However, aberrant antigen-presenting capac- 
ity may be induced by lymphokines, and such inappropri- 
ate expression of MHC class II molecules (e.g., on epithe- 
lial cells) is thought o play a role in autoimmune disease 
[251. 
4.1. AMA in PBC:  the M2 ant igen 
PBC was the first disease unequivocally recognised as 
being associated with AMA of a characteristic specificity 
[26]. Once the properties of the antigenic target for these 
antibodies, designated as 'anti-M2', had been defined, it 
was established that high and persistent titres of anti-M2 
antibodies (both lgG and IgM) are found in over 95% of 
cases of PBC. The M2 antigen was found to be loosely 
associated with the inner surface of the inner membrane of 
all mitochondria tested, from human to fungal, and anti-M2 
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antibodies were shown to cross-react with many bacteria, 
anti-mitochondrial ctivity, for example being absorbed 
out of PBC sera by E. coli (reviewed in [5]). 
It was also established that M2 consists of a 'family' of 
co-purifying peptides of differing M r and isoelectric point. 
The predominant antigen was shown to have a M r of 
70-74, which is species dependent, but tissue independent 
within a given species. However, mitochondria of one 
species will totally absorb out from PBC sera reactivity 
against any other mitochondria, even though the M r of 
corresponding antigens are different. 
The entire 'family' of M2 autoantigens was found to 
cover a spectrum of M r from around 75 000 to 36 000, and 
probably to contain no more than about six members. 
However, different PBC sera were shown to detect differ- 
ent numbers of M2 antigens in a given mitochondrial 
preparation, and with differing relative intensities. 
4.2. Identi~ of  the M2 antigens 
It took a surprisingly long time after their original 
detection and characterisation for the molecular identities 
of the members of the M2 family to be established. The 
first to be identified was the predominant one, of M r 
around 70000. Immunoscreening of gene expression li- 
braries, and the sequencing of cDNA clones coding for the 
antigenic peptide led to the unambiguous demonstration 
that that antigen was the E2 component (dihydrolipoamide 
acetyltransferase) of the pyruvate dehydrogenase complex 
(PDC) (reviewed in [5]). 
All of the previously established properties of the M2 
antigens were compatible with this identity. For example, 
the M r of PDC-E2 does indeed significantly vary as 
between species. The reason for the delay in realising that 
the major M2 autoantigen was such a major, and well- 
studied, mitochondrial constituent was primarily a trivial 
one. M2 co-purified with the inner mitochondrial mem- 
brane-albeit that it was well known that it could readily be 
detached therefrom. In the mind-set of most investigators, 
PDC was a constituent of the matrix, and so its possible 
identity with M2 was never considered. 
4.3. The OADC family 
PDC is one of three related multi-enzyme complexes, 
the oxo-acid dehydrogenase complexes, (OADC), all lo- 
cated in loose association with the inner surface of the 
inner mitochondrial membrane. The other two complexes 
are the 2-oxoglutarate dehydrogenase complex (OGDC) 
and the branched chain 2-oxo-acid ehydrogenase complex 
(BCOADC) [27]. Each has a generally similar similar 
overall structure and catalytic mechanism. 
The E2 components of the OADC are evolutionarily 
highly conserved, both between species and between the 
different complexes. For example, the overall degree of 
sequence homology, when conservatively substituted 
residues are included, is 58% between rat and E. coli 
PDC-E2, 52% between rat PDC-E2 and bacterial OGDC- 
E2 and 47% between rat PDC-E2 and human BCOADC-E2 
[281. 
Mammalian and yeast PDC have an additional subunit 
which co-purifies with, but which is different from E2. 
This subunit, protein X, contains at least one lipoate 
moiety, which can be reductively acetylated [29]. E2 and X 
are present in the same ratio in different issues of rat, so X 
is unlikely to be a tissue-specific isozyme of E2 [30]. 
Moreover, there are no reports of the other OADC contain- 
ing a protein corresponding to X, so its function remains to 
be clarified. 
4.4. IdentiO, of  the other M2 autoantigens 
Once E2 of PDC was recognised as the major autoanti- 
gen of the M2 cluster, it was not long before the others 
were identified. They were all shown to be constituents of 
one or other of the OADC. 
All PBC sera that react with PDC-E2 also react with a 
peptide of M r 50000-56000,  shown to be identical to 
protein X of PDC [31-33]. This is due to cross-reactivity 
of antibodies, since absorption of PBC sera with human 
recombinant PDC-E2, also removes reactivity against he 
56 kDa peptide. However, whilst PI3C sera reactive against 
PDC-E2 also recognise protein X from human, bovine and 
porcine mitochondria, they do not react against protein X 
from rat or mouse. 
In view of the highly conserved nature of the lipoyl 
domains of the E2s (and protein X), it was not surprising 
that the E2s of OGDC and BCOADC respectively were 
also shown to be autoantigens of the M2 family. Immuno- 
blotting of E2 from OGDC with PBC sera showed that (for 
some sera) that protein corresponded to an M2 autoantigen 
of M r 48000-50000 [28]. Similarly, preparations of puri- 
fied BCOADC-E2 reacted specifically against some (but 
not all) PBC sera to reveal an M2 autoantigen of molecular 
mass 50-52 kDa. 
Further confirmation of these identities came from en- 
zyme-inhibition studies and from testing sera with a hu- 
man fetal liver cDNA clone of BCOADC-E2 [34]. Absorp- 
tion of PBC sera with the recombinant fusion protein 
completely and specifically removed all reactivity against 
the 52 kDa peptide(s) in one- or two-dimensional im- 
munoblots. 
During these studies it became apparent hat the E2s 
were not the only constituents of the OADC to be M2 
autoantigens. When PBC sera were immunoblotted against 
the purified heterodimeric El component of bovine PDC 
(the decarboxylating, pyruvate dehydrogenase), some were 
found to react against E1 ~ (41 kDa) and a proportion of 
these also reacted against El/3 (34-36 kDa). However, no 
reactivity was observed against El from E. coli PDC [35]. 
This finding was confirmed in another study [36], which 
also showed that PDC enzyme activity was inhibited by 
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affinity purified PBC antisera against PDC-E1. Further 
confirmation of the identity of El ~ of PDC as a member 
of the M2 family of autoantigens was made using the 
recombinant human enzyme [37]. Thus, the common fea- 
ture of M2-AMA is reactivity against constituents of one 
or other of the complex dehydrogenases. 
4.5. Frequency of occurrence of antibodies to individual 
M2 antigens 
As mentioned earlier, not all PBC sera react against all 
antigens of the M2 cluster. However, the apparent M r 
values cited above for the individual antigens, can be seen 
to be overlapping, partly because of interlaboratory varia- 
tions arising from the anomalous mobility of E2 enzymes 
in polyacrylamide gel electrophoresis. So, except in cases 
where defined antigens have been used in the assays, there 
is some ambiguity in comparing results from various sur- 
veys on the frequency of antibodies to the individual 
antigens in sera from a set of PBC patients. Also, except in 
the case of PDC-E2 and protein X, where reactivities 
against each always apparently co-exist, it is not clear if 
there is any clustering of antibodies to particular sets of 
antigens. This last uncertainty relates to the issue of the 
extent to which there is cross-reactivity of antibodies 
between antigens. That may depend upon serum dilutions 
used in immunoblots, which again vary between laborato- 
ries. With those reservations, a rough averaging of all 
published ata gives a frequency profile as shown in Table 
1. From this it can be seen that between 98% and 100% of 
PBC sera react with one or other of the autoantigens with 
around 96% of PBC sera reacting with PDC-E2 (and 
protein X) and with around half recognising all three E2s. 
4.6. Reactivity of PBC sera against E3 
Dihydrolipoamide dehydrogenase, E3, is a common 
subunit of all three OADC. It is present in much smaller 
amounts than are the corresponding E2s; for example, in 
bovine PDC there are only 6 dimers of E3 compared to 60 
copies of E2 [27]. With an M r of 55 000, which is in the 
range of the apparent M r values of the established M2 
Table 1 
Frequency of occurrence of AMA to specific M2-antigens in PBC 
Complex Subunit Apparent molecular AMA-posit ive a (%) 
mass (kDa) 
PDC E1 oz 41 53 
PDC E1/3 34-36 4 
PDC E2 70-74 96 
PDC X 50-56 96 
OGDC E2 48-50  74 
BCOADC E2 50-52 56 
All E2s - = 50 
At least one E2 - = 99 
Average of published ata using defined antigens. 
autoantigens, it seemed possible that reactivity against E3 
by PBC sera might have been overlooked, particularly if 
titres of anti E3 AMA were low. 
In a study on this question [38], anti-E3 antibodies were 
indeed detected by immunoblotting with sera at an initial 
dilution of 1:100 (instead of the conventional 1:1000). 
However, not only was this reactivity found with 11 of 29 
PBC sera, but 10 of 40 control sera also gave similar 
results. Furthermore, reactivity was only detected against 
mammalian E3; there was no reactivity against recombi- 
nant E. coli expressing the yeast mitochondrial enzyme or 
over-expressing the E. coli E3 protein. Consequently the 
anti-E3 AMA thus detected are not in the M2 cluster, but 
might be characterised asan example of NOMA, discussed 
earlier. 
4. 7. Enzyme inhibition by M2-AMA 
Confirmation of the identity of the M2-autoantigens, 
has come from studies on the inhibition of each of the 
OADC enzyme activities by AMA. Such studies not only 
indicated that dominant epitopes are associated with cat- 
alytic sites, they also indicated that the spectrum of autoan- 
tibodies that inhibit the enzyme activity of PDC is wider 
than simply the AMA against the individual subunits as 
recognised by immunoblotting. Thus, evidence has been 
presented for the existence, in a set of PBC sera, of high 
titres of inhibitory antibodies not absorbed by PDC-E2, or 
recognising it on immunoblots [39]. It was concluded that 
what was being detected was a major new class of AMA 
reactive against a conformational epitope of the native 
enzyme complex. For example, inhibitory capacity could 
be totally absorbed out by intact PDC, but when inhibitory 
antibody was eluted and then passed through a PDC-E2 
column, only a fraction of the inhibitory capacity was 
removed, although the residual, inhibitory antibody no 
longer reacted against PDC on immunoblotting. 
4.8. Cross-reactivity of antibodies to mitochondrial E2s 
Not all PBC sera react with all three OADC-E2s, and 
sera may be identified that react uniquely with one or other 
of each of them. This indicates that such AMA may be 
peptide specific. Indeed, most published work on the spe- 
cific identification of individual antigens clearly points to 
all anti-E2 antibodies being peptide-specific, with the ex- 
ception of the generally accepted finding of cross-reactiv- 
ity of antibodies recognising E2 and protein X of PDC. 
Given the conserved nature of the lipoyl domains of E2 
and noting that for a given E2 there is cross-reactivity of
antibody across all eukaryotic species tested, from yeast o 
man [27,40-43], the specificity of antibodies to each of the 
E2s is surprising. However, absolute peptide-specificity 
may not in fact, be universal. For example, it has been 
shown that antibodies eluted from one band on an im- 
munoblot of whole mitochondria may react back on a 
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second blot with that band only or also with some, or all of 
the other bands initially detected, depending on the PBC 
serum tested [44,45]. 
Other work has shown that antibodies reacting respec- 
tively against OGDC-E2 and BCOADC-E2 all cross-react 
with the other antigen, sometimes with apparently equal 
avidity, sometimes more weakly [43]. However, no cross- 
reactivity was observed between antibodies reactive against 
PDC-E2 (and protein X), and the other two classes of E2. 
The apparent interlaboratory differences in such find- 
ings may relate to the particular set of sera used, (since 
there is a wide spectrum of AMA profiles of individual 
PBC sera) and/or to precise experimental conditions. For 
example, the degree of denaturation of a peptide on a blot 
might determine whether or not it bound an antibody 
recognising a conformational epitope. 
4.9. Cross-reacti~,i~ of anti-M2 AMA with bacteria 
Following an early report of reactivity, of PBC sera 
against Paracoccus denitrificans [46], a growing body of 
evidence accumulated indicating cross-reactivity of AMA 
against prokaryotic antigens homologous to corresponding 
mitochondrial enzymes. Thus, reactivity was reported 
against E. coli [41,47], Klebsiella pneumoniae, Proteus 
mirabilis, and Staphylococcus aureus [44]. More recently, 
has been the demonstration of specific cross-reactivity 
against a whole range of other bacteria, including rough 
mutants of Salmonella minnesota [48]. 
Early work was open to criticism on the grounds that 
patients with PBC frequently have a history of recurrent 
urinary tract infections (UTI) [49], and sera from such 
patients exhibited anti-E, coli antibodies, unrelated to AMA 
[47]. However, when tested against subcellular extracts of 
E. coli, PBC sera (and not controls) reacted strongly with a 
characteristic set of antigens on Western blotting, and this 
reactivity could be absorbed out by mitochondria [41]. 
Moreover, antibodies eluted from individual bands on 
immunoblots of PBC sera against extracts of a variety of 
bacteria, reacted back against all bands of all species 
tested, and also against the major M2 antigen of mito- 
chondria [44]. Also, antisera raised in rabbits against rough 
mutants of S. minnesota, react against a characteristic 
profile of M2 antigens on immunoblotting against mito- 
chondria [48]. 
Once the identity of the M2 antigens was established, 
the identity of the cross-reacting prokaryotic antigens was 
quickly determined. The E. coli antigen of M r around 
80000 was shown to be its PDC-E2, whilst that of M r 
50000 was the OGDH-E2 [50]. E. coli do not contain 
BCOADC [51], but this enzyme is found in other bacteria, 
and M2 AMA have been shown to react with BCOADC-E2 
from P. putida and P. aeruginosa [43]. 
These cross-reactivities were not surprising, in view of 
the conserved structure of the family of E2 transacylases. 
However, there is doubt as to the true extent of cross-reac- 
tivity between antibodies against he respective mitochon- 
drial and prokaryotic antigens. In the light of a range of 
studies (reviewed in [5]) the current consensus is that 
whilst cross-reactivity exists between anti-mammalian 
(and yeast) antibodies and microbial E2s, and vice versa, 
this is of low affinity, and PBC sera contain distinct sets 
antibodies directed against mammalian and bacterial en- 
zymes respectively. Unlike the case of the E2 enzymes, 
there are no phylogenetic homologies between the respec- 
tive PDC-Els of the mitochondrial and bacterial com- 
plexes. It is therefore not surprising that sera which react 
with bovine E1 a do not recognise bacterial PDC-E1, even 
at low serum dilution [35]. 
4.10. Epitopes recognised by anti-E2 AMA 
The major M2-antigens are members of the highly 
conserved E2 transacylase family, nevertheless, most of 
the corresponding antibodies are peptide specific, albeit 
with some cross-reactivity, usually of low affinity. Also, a 
significant fraction of the enzyme-inhibitory AMA bound 
by intact PDC is not detectable by immunoblotting, or 
bound to an affinity column of PDC-E2 [39]. So the AMA 
include a set of high-titre antibodies directed at a confor- 
mational epitope(s) of the whole complex. Nevertheless, a 
considerable amount is now known about immuno-domi- 
nant epitopes for antibodies against particular E2s, de- 
tectable by immunoblotting. 
Two independent studies initially localised the main 
immunogenic region of PDC-E2 to the lipoyl domain 
[48,52]. In a subsequent s udy [49] it became clear that the 
short peptide around the lipoyl region, although central to 
the dominant epitope, is itself a very weak antigen. A 
minimum of 75 amino acids encompassing that peptide 
(residues 146-221) were required for significant autoanti- 
body binding, but virtually the whole of the inner domain 
was necessary for full immunological reactivity; the 93 
amino-acid sequence, residues 128-221, from the total 
sequence, 128-229. 
The considerable length of peptide required for full 
antigenicity suggests that the epitope is a conformational 
one, which is at variance with the usual method of detec- 
tion. However, conformational epitopes may be recognised 
as a set of primary sequences [53]. Since the four major 
mitochondrial ntigens (the three E2s plus protein X) plus 
the corresponding bacterial antigens all have in common 
the possession of one or more lipoyl domains, it could thus 
be argued that the main immunogenic region in each is 
centred around such a domain (which accounts for weak 
cross-reactivity), with extended flanking regions being re- 
sponsible for peptide specificity and full reactivity. 
4.11. The role of lipoate in antigeniciO, 
There is some disagreement as to whether lipoate itself 
is involved in antibody recognition in PBC. Many of the 
116 tt. Baum / Biochimica et Biophysica Acta 1271 (1995) 111-121 
peptides used to probe for the immuno-dominant epitope 
would not have been lipoylated; yet lipoic acid is a mito- 
gen and augments antibody responses [54,55]. Neither 
lipoic acid itself or lipoamide were found to be antigenic 
(44). More significantly, the H protein of the glycine 
cleavage system of chicken liver, which has a lipoic acid 
co-factor, and homology with E2 around the lipoyl attach- 
ment site, does not react with PBC sera [56]. However, it 
does seem that the presence of a lipoyl residue within the 
immuno-dominant domain is crucial for effective recogni- 
tion of E. coli E2s by AMA [56]. Matters are not so clear 
cut in the case of antibodies against the mitochondrial 
enzymes. One group has concluded from studies involving 
site-directed mutagenesis that lipoate could not be in- 
volved in antigen recognition [57]. Another has produced 
evidence that lipoylation is essential for full antigenicity 
[58]. 
5. Other antibody systems associated with PBC 
In addition to the anti-M2 antibodies, a number of other 
antibodies have been described that may also be disease 
specific for PBC. The least defined of these are three sets 
of precipitating antibodies, designated M-A, M-B and M-C 
[59,60]. The relationship, of these with other antibodies of 
defined specificity has yet to be fully explored. 
Another ill-defined antibody associated with PBC is 
that designated as anti-M8. This recognises a trypsin-sens- 
titive antigen which co-purifies with outer mitochondrial 
membranes, [61]. A precise protocol has been defined for 
the isolation of M8 (usually from pig kidney microsomes), 
but its identity is unknown. It is non-organ-specific, and 
detectable by ELISA, but not by immunoblotting. Anti-M8 
seems to be specific for PBC, and there is claimed to be a 
correlation between its detection and disease progression. 
5.1. Anti-M4 antibodies 
Another antibody associated with PBC is the so-called 
anti-M4. The M4 antigen co-purified with the outer mito- 
chondrial membrane and was insensitive to trypsin [62-64]. 
Anti-M4 antibodies were preferentially observed in pa- 
tients with features not only of PBC, but also of chronic 
active hepatitis (CAH), a so-called 'mixed form' pathol- 
ogy. The identity of M4 was established when anti-M4 
positive and negative sera were tested against a battery of 
putative antigens. There was a correspondence b tween 
reactivity against a standard preparation of M4 antigen and 
against sulphite oxidase [65]. Also, anti-M4 reactivity could 
be absorbed out of PBC sera by sulphite oxidase coupled 
to Sepharose. 
Sulfite oxidase is an enzyme of the intermembrane 
space but its precursor binds to the outer membrane [66]. It 
is an evolutionarily highly conserved enzyme, also found 
in bacteria. [67], and possesses both a haem prosthetic 
group and a functional molybdenum centre. Little is yet 
known of the antigenic epitope(s), but apparently the en- 
zyme is not inhibited by anti-M4 positive PBC sera [65]. 
Although the identity of M-4 is clearly established, there is 
now some doubt as to whether the antibodies are truly 
disease specific [68]. Until this issue is clarified, specula- 
tion as to the role of anti-M4 in PBC is premature. 
5.2. Anti-M9 antibodies 
When anti-M2 positive, anti-M4 negative sera were 
tested against submitochondrial particles from rat liver, 
treated to remove M2 antigens, a positive reaction was still 
frequently detected by ELISA [69,70]. The antibody thus 
recognised was claimed to be PBC-specific and directed 
against an antigen, designated as M9. 
The identity of M9 was subsequently established by the 
testing of anti-M9 positive sera against a large set of 
defined enzymes. It transpired that M9 is not a mitochon- 
drial constituent after all, but corresponds to a cytoplasmic 
enzyme, glycogen phosphorylase [71]. A complication of 
the this work was the finding that sera from a significant 
number of normal subjects also reacted with commercially 
available muscle glycogen phosphorylase, but not with the 
M9 antigen preparation. Presumably the commercial en- 
zyme contains other antigens, recognised by naturally oc- 
curring antibodies. As to the real disease specificity of 
anti-M9 antibodies, this too (as with anti-M4) has now 
been questioned [68]. 
5.3. Antibody titres and disease staging in PBC 
The appearance of AMA in association with PBC is 
parallelled by an increase in levels of serum im- 
munoglobin, particularly IgG3 and IgM, although antibody 
is not restricted to those classes [72]. Also, a large increase 
in AMA titre has been reported with disease progression 
[73], with a significantly higher titre of AMA in symp- 
tomatic than in asymptomatic patients at presentation [74]. 
However, specific antibody titre is not a simple diagnostic 
indicator of disease progression. This whole question is a 
complex one (reviewed in [5]), confounded by disputes as 
to the validity of using titres of anti-M4, -M8 and -M9 in 
disease staging and prognosis. 
6. Stimulus for AMA production in PBC 
With detailed knowledge of the characteristics of AMA 
associated with PBC, in particular anti-M2, two key ques- 
tions arise: what is the stimulus for their production and 
persistence in such high titre, and what is their relationship 
to the pathogenesis of the disease? There must be some 
powerful antigenic drive; peripheral blood lymphocytes 
from PBC patients produce those AMA in a manner 
suggesting that the corresponding B-cell clones are maxi- 
mally stimulated [75]. 
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Although anti-M2 AMA are not exclusive to PBC, 
(they are sometimes found in diseases of other primary 
pathology, [76,77]), they cannot simply be a response to 
tissue damage, since such antibodies are not detectable in
any other destructive disease of the liver, (except, in 
chronic active hepatitis, when there is a 'mixed' pathology 
with PBC). 
The initial event in an immune reaction involves the 
presentation of a degraded fragment of the primary antigen 
in association with a major histocompatibility complex 
(MHC) class II molecule at the surface of an antigen-pre- 
senting cell. Such presentation stimulates CD-4 + helper 
T-cells with receptors recognising that MHC-peptide com- 
plex, and those T-cells then stimulate antibody production 
by B-lymphocytes recognising a conformational epitope of 
the primary antigen. Biliary duct epithelial cells in PBC 
express uch class II molecules, both HLA-DR and DQ, 
inappropriately [24,78]. Hence, it might be suggested that 
such expression (possibly in response to a prior inflamma- 
tory event), would have a role in stimulating AMA produc- 
tion, but only if peptides derived from the antigens them- 
selves were presented by those class II molecules. Because 
of the way that such MHC-peptide complexes are assem- 
bled, this would be more likely if the primary antigens 
were also expressed at the same cell surface. 
Since the OADC are normally in mitochondria deep 
within the cell such an expression might seem unlikely. 
However, evidence has been reported [79] suggesting that 
at least the E3 subunit of these enzymes may serve an 
additional function, that is specific to a location in the 
plasma membrane. Also as mentioned earlier, there is a 
precedent for cell surface presentation of mitochondrial 
antigens, in the co-expression with a class I-like MHC 
molecule of a peptide derived from ND1, [1,2]. 
Direct evidence of normal surface expression of M2 
antigens is controversial, and is reviewed elsewhere [5]. 
What does seem to be better established, however, is the 
disease-specific appearance, at the surface of bile duct 
epithelial cells in PBC, of antigen recognised by anti-M2 
AMA. This has been demonstrated on tissue sections of 
bile ducts [80] and using anti-E2 antibodies on cultured 
biliary epithelial cells from PBC (and control) livers [81]. 
There have been a number of suggestions as to how 
subunits of OADC, might come to be expressed at the cell 
surface, in a tissue and disease-specific manner. For exam- 
ple, there might be a somatic mutation in the leader 
sequence [82] of the cytoplasmically synthesised E2 sub- 
units, resulting in a disruption of the normal docking and 
import pathway. This could result in accumulation of 
peptides in the cytoplasm, and their eventual relocation to 
the cell membrane, possibly in association with MHC 
molecules [83]. However, it must be borne in mind that 
cell-surface antigenicity as detected by indirect immuno- 
fluorescence would not discriminate between an authentic 
E2 subunit and any other molecule that might mimic it in 
binding antibody. It should also be borne in mind that 
AMA production, although driven by activated CD4 + 
T-cells, comes from B-cells that would require to have 
recognised and taken up intact antigen from the circula- 
tion. 
Another difficulty in explaining antibody production 
simply in terms of antigen expression on liver ductular 
cells is evidence from orthoptic liver transplantation. Anti- 
E2 antibodies persist in high titre in PBC patients follow- 
ing such procedures [4]. 
A more persuasive xplanation of the initiation of anti- 
body production relates to molecular mimicry by microbial 
antigens. As discussed earlier, PBC sera react against E2s 
of common bacteria, (although much of such reactivity 
may reflect a subset of bacteria-specific antibodies). As 
has also been mentioned, animals immunised with the 
fragile R-mutants of Enterobacteria manifest high titres of 
anti-E2 reactivity. It also should be borne in mind that 
there is unambiguous cross-reactivity of AMA against 
antigens (including El) from mitochondria of fungi such 
as yeast. 
It is, therefore, tempting to speculate that the initiation 
of antibody production could arise from bacterial or fungal 
infection. In this connection, it is relevant hat the inci- 
dence and prognosis of PBC is correlated with chronic 
urinary tract infection (CUTI) and bacteriurea [84], and 
that CUTI and fungal infections, like PBC, are particularly 
common in middle-aged women. It is also important o 
note that a high proportion of patients with CUTI, but 
normal iver function exhibit low titres of specific antibody 
against PDC-E2, and that patients with PBC and bacteri- 
urea exhibit the presence of R-forms of the infecting 
organism [85]. 
The frequent presence of antibodies against El c~, which 
has no homology, might argue for a fungal involvement in
antigen drive. However, these antibodies might arise later 
in disease simply as a secondary result of tissue damage. 
Certainly it would not be surprising that another enzyme 
from the same complex should also become an antigen. As 
in the immunology of hepatitis B, large complexes tend to 
be treated as a single antigen by the immune system 
[86,87]. 
Another possibility to explain the appearance of anti-E1 
antibodies is currently under investigation (Baum, H. and 
Butler, P., unpublished observations). This is that these are 
anti-idiotype antibodies directed at those anti-E2 antibod- 
ies recognising the conformation of the E2 binding site for 
El. 
6.1, Role o f  AMA in the pathogenesis of  PBC 
Any ideas on pathogenic mechanisms in PBC have to 
start with anti-M2 AMA. These are so highly focused and 
so disease-associated that there is no doubt as to their 
relevance. However, most workers agree that the antibod- 
ies themselves are not a prime cause of tissue damage. For 
example, when anti-M2 AMA have been raised in animals 
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there has been no evidence of liver damage; although the 
epitopic specificity of such antibodies is not identical to 
that in PBC (reviewed in [5]). Also, there is no recurrence 
of PBC following liver transplantation despite persistence 
of anti-M2 AMA, although that picture might be con- 
founded by immunosuppressive th rapy. 
Consequently, it is not entirely ruled out that antibody 
may play a direct role in tissue damage, as for example is 
the case in myasthenia gravis [88]. For example, the 
immunoglobulin deposits that have been detected on the 
surface of bile duct epithelial cells, might lead to immune- 
complex mediated cytotoxicity [89]. It is also just possible 
that specific internalisation of antibody bound to inappro- 
priately expressed surface antigen could lead to a cytotoxic 
effect hrough inhibition of key metabolic pathways. 
Large amounts of circulating immune complex are pre- 
sent in PBC [90,91]. These may account for arthalgias and 
rashes seen in the disease, but they are probably not 
associated with ductular damage [92]. 
ies might all be driven by a single clone of a T helper cell 
recognising an epitope derived from any protein in a 
complex, and not necessarily that corresponding to the 
immuno-dominant epitope for the antibodies. The analogy 
is again the immune response to hepatitis B [95]. Such 
speculation for example would allow the hypothesis that 
the T-cell epitope might be found in E3, which is common 
to all of mitochondrial OADC, and might be present at the 
cell surface. 
Direct attempts to identify epitopes to which helper 
T-cells of PBC patients might respond have led to conflict- 
ing reports, (reviewed in [5]). Perhaps the most clear-cut 
evidence relating to T-cell epitopes comes from studies 
involving the cloning of CD4 +, CD8- cell lines from 
patients with PBC [52]. Clones were screened for the 
production of IL-2 in response to stimulation by putative 
antigens. Two such clones were reported to respond specif- 
ically to PDC-E2, and one to BCOADC-E2. If confirmed, 
this would be direct evidence that the T-cell drive in AMA 
production is also polyclonal and peptide specific. 
7. Role of T-cells in pathogenesis of PBC 7.1. Molecular mimic~ between antigens and class H HLA 
It is generally agreed that T-lymphocytes will be central 
to any definitive account of pathogenetic events in PBC. 
Whilst non-specific ytotoxic K-cells might conceivably 
be involved, most interest is in possible roles for CD8 ÷, 
cytotoxic T-cells, and for CD4 ÷, helper cells. 
Cells of both classes infiltrate the bile ducts in PBC 
[23,93,94], and it is certainly possible that CD8 + cells are 
directly involved in attacking epithelial cells. Cytotoxic 
T-cells would normally be involved in a response to a 
'foreign' peptide, made in the cell and presented by MHC 
class I molecules. Hence, a CD8 ÷ mediated process could 
be speculated if abnormal E2 peptides (e.g., with a mutant 
leader sequence) accumulated in the cytoplasm and were 
fragmented and disposed of in association with class I 
expression. However, there is no evidence of up-regulated 
class I expression in bile ducts in PBC, or of CD8 ÷ cells 
recognising any candidate pitope from a mitochondrial 
antigen. 
Involvement of CD4 ÷, T helper cells is more clear-cut. 
The high titre of AMA is evidence of this, and the aberrant 
expression of class II HLA, on bile duct cells in PBC, 
suggest hat it might be presentation of antigen by such 
molecules that activates CD4 ÷ clones to drive primed 
B-cells to antibody production. In such a model, class II 
expression would be continuously upregulated by the lym- 
phokines released by the stimulated T helper cells. Also, 
the fact that PBC may be partially MHC-restricted, with an 
association with HLA-DR8, suggests that a CD4 ÷ epitope 
is involved that binds preferentially to that class II 
molecule. 
In speculating as to what that epitope might be, it 
should be noted that a set of clonally distinct B-cells 
producing a spectrum of peptide-specific anti-M2 antibod- 
An alternative approach to a possible link between 
CUTI and, in some cases, the subsequent onset of PBC 
came from a consideration of possible molecular mimicry 
between all E2 antigens and some separate self-antigen, 
possibly one of the MHC molecules expressed, in those 
patients progressing to PBC, on the bile duct epithelial 
cells. A data base search for similarities between the 
immuno-dominant lipoyl domain of E. coli PDC E2 and 
any region of a class II MHC molecule, revealed a highly 
significant correlation with a sequence in the invariant 
region of HLA-DRc~ [96]. The similarities between this 
DRa motif and the lipoyl domains of each of the E2s 
examined were as great as between the various species of 
E2 themselves, and in this regard HLA-DR ce was found to 
be virtually unique among all the human proteins in the 
databases. This suggested immunological cross-reactivity, 
and a possible key role of HLA-DR~x in antigen drive. 
Central to that common motif is the triplet of amino acids, 
DKA, where K is the lysine that is lipoylated in the native 
E2s. Interestingly, both glycogen phosphorylase (M9) and 
sulfite oxidase (M4) contain that triplet. In a single protein, 
the appearance of DKA might be a simple coincidence, but 
the sharing of this triplet among this set of, PBC-related, 
M-antigens is quite striking. 
However, these sequence similarities between the E2s 
and DR c~ are most unlikely to constitute a common B-cell 
epitope. The conformation i this region in E2 [97] is quite 
different from that of the equivalent motif in the MHC 
molecule [98]. Instead, it would have to be proposed that 
molecular mimicry occurs when these peptides bind as 
processed fragments to an MHC class II molecule. It was 
therefore very significant indeed when it was realised that 
it had already been shown in two separate studies, [99,100], 
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that the identical peptide, from the identical region of the 
mouse I-Ec~ chain (the mouse equivalent of HLA-DR) is a 
major self-antigen, presented by MHC I-A (equivalent to 
HLA-DQ). 
7.2. A model,for the pathogenesis of PBC 
These considerations led to an hypothesis [96] where 
the response to an infection (be it chronic fungal, or 
recurrent UTI) involves stimulation of T-cells recognising 
the highly immunogenic lipoyl region of one or other E2 
of the infecting organism as presented in association with 
HLA by antigen presenting cells. These CD4 + T-cells are 
thus primed to overcome tolerance when they recognise 
the similar sequence, from HLA-DR, presented on a class 
II antigen (preferentially DR8?) on the surface of biliary 
epithelial cells. Initial class II presentation might be coinci- 
dental, and due to an independent inflammatory event, but 
once initiated the process would drive itself. Also, such 
up-regulation might lead to presentation of the correspond- 
ing peptides from mitochondrial E2s, particularly if the 
inflammatory cascade led to an increased turnover of 
mitochondrial constituents. 
Some of these CD4 + cells recognising these HLA-pre- 
sented antigens might be cytotoxic and/or recruit CD8 + 
cells, others would provide help for B-cells producing 
AMA against a repertoire of conformational epitopes of 
constituents of complexes containing peptides with the 
same central motif. These proteins would include those of 
OADC of mitochondrial origin, particularly as tissue dam- 
age led to the release of mitochondrial complexes for 
direct exposure to the immune system. 
Indirect support for the validity of this model comes 
from a consideration of antibodies, found in association 
with PBC, but highly characteristic of chronic active hep- 
atitis. These react against he asialoglycoprotein receptor 
[101], normally found on the hepatocyte surface. A search 
of the database revealed that this protein also has a region 
remarkably similar to the immuno-dominant epitope of the 
E2s [102]. In the light of this, it is also possible that 
anti-E2 antibodies might actually react with this protein, 
and account for the cell-surface reactivity mentioned previ- 
ously. 
Further support for this model also comes from the 
observation [102] that another unrelated, protein shares the 
rare motif that these considerations focus upon. This is the 
heat shock protein, hsp 65. This protein too is inappropri- 
ately expressed on biliary epithelial cells in PBC [103]. 
8. Other implications of molecular mimicry 
The bulk of this review has focused on the AMA of 
PBC. However, the theme of molecular mimicry devel- 
oped from such consideration might well account for all of 
the other disease-specific AMA. It also gives insight into 
the occurrence of PBC-specific antibodies directed at the 
nuclear glycoprotein gp210, referred to earlier. Recent 
work [104] has identified the epitope recognized by those 
antibodies. That epitope is very similar indeed to peptides 
in the gene products of two bacterial species. Interestingly, 
we have noted (Baum, unpublished observation) that that 
same sequence is similar to one in human thyroglobulin. 
As mentioned earlier, autoantibodies to that protein are 
also found in PBC. 
In more general terms, the model for the pathogenesis 
of PBC proposed in the last section has been developed 
into a general hypothesis for the molecular basis of au- 
toimmune disease, from insulin-dependent diabetes melli- 
tus to the progression from HIV-infection to AIDS 
[ 102,105,106]. This model includes aspects of genetic pre- 
disposition, and from that viewpoint may give an insight 
into pathological processes underlying diseases, (discussed 
elsewhere in this Volume), arising from maternally inher- 
ited point mutations in mitochondrially synthesised pep- 
tides of Complex I. 
For example, the late onset of symptoms in LHON 
which may then manifest as multiple sclerosis (MS) in 
some cases of a specific point mutation in ND4 [107], 
might suggest he precipitation of an autoimmune process 
in a predisposed subject. As mentioned earlier, at least one 
of the Complex I peptides, NDI, may be exposed at the 
cell surface in association with histocompatibility antigen 
[1,2]. Is it therefore possible that the mutations generate 
peptides which, if expressed in association with Class II 
HLA, (rather that class I, as normal), might mimic peptides 
of an environmental immunogen recognised by the pa- 
tients' helper T-cells, thus triggering an autoimmune cas- 
cade? For example, the 14-mer peptide around the com- 
monest point mutation in ND4 becomes (after mutation of 
arginine to histidine at position 340), very similar to a 
sequence in the Tu-elongation factor of many microorgan- 
isms, (Baum, H. and Cunningham, P., unpublished obser- 
vation). Alternatively, one might speculate that any inher- 
ited mutation that interfered with the assembly of mito- 
chondrial complexes might lead to a greater turnover and a 
greater likelihood of presentation of a range of fragments 
in association with HLA antigens. Accidental circum- 
stances might lead to class II expression in target issue, 
and thus set the stage for precipitation of autoimmune 
disease. This might be through a subsequent infection with 
an organism, a peptide of which mimicked one of those 
fragments. (It should be remembered, in this connection 
that the ND peptides of microorganisms are very similar to 
their mitochondrial counterparts.) 
On the other hand, in the case of a somatic mutation, 
resultant peptides would normally be presented on the cell 
in which it occurred, in association with class I HLA, 
leading to a cytotoxic response mediated through CD8 + 
cells. Indeed, it might be argued that this is the normal fate 
of a cell in which somatic mutation results in the synthesis 
of novel mitochondrial peptides. Consequently, it might be 
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suggested that the exponential rate of accumulation of 
mitochondrial mutations with age, (as discussed elsewhere 
in this Volume), represents not so much an autocatalytic 
process, but an age-related ecline in the competence of 
immunosurveillance. 
In the less likely circumstance where a newly arising 
mutant peptide were class II associated, CD4 ÷ cells would 
be stimulated. These in turn might then recognise a normal 
self-peptide, presented elsewhere, that mimicked the mu- 
tated mitochondrial one, leading to autoimmune attack on 
that target tissue. For example, we have noted a strong 
similarity between a sequence in ND2 of Complex I and 
one in the neuronal acetylcholine receptor (Baum, H., 
unpublished observation). A mutation increasing that simi- 
larity might therefore have pathological consequences. 
Interestingly there has been a report [108] linking 
Alzheimer's disease with a point mutation of the alanine at 
position 331 of ND2. Also, point mutations in ND1 seem 
to predispose to Alzheimer's disease and Parkinsonism 
(see elsewhere in this Volume). Is there an autoimmune 
component to these very late onset manifestations of inher- 
ited mitochondrial mutations, and might somatic mutations 
with aging predispose to an autoimmune pathology as well 
as one of energy deficiency? 
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